Gastric Adenocarcinoma
- Home
- Solutions
- By Diseases
- Gastric Diseases
- Gastric Adenocarcinoma
Gastric adenocarcinoma remains a dreadful ailment and is the third cause of cancer mortality across the globe. Protheragen is a research service provider focusing on the specific area of preclinical drug development for gastric adenocarcinoma. Our service offering is comprehensive as we can assist you in diagnostic development, therapy development, and disease model development.
Around 95% of stomach cancer cases are gastric adenocarcinoma and it is associated with significant mortality across the globe. The majority of these sporadic gastric adenocarcinomas result from persistent inflammation. Gastric adenocarcinoma is diagnosed by different histological and molecular features, which classify these tumors into distinct subtypes. These cancers differentiate due to the etiological mechanisms of the disease and different predisposing factors and individual characteristics.
Fig.1 Classification of gastric adenocarcinoma. (Ivey, A., Pratt, H., and Boone, B. A., 2022)In general, the major etiological determinants for gastric adenocarcinoma can be grouped into three main areas which include environmental factors, genetic and epigenetic changes. Concerning the environmental factors, Helicobacter pylori and EB virus infections are assumed to be the most important causes of gastric adenocarcinoma. Moreover, numerous DNA changes have been found in gastric adenocarcinoma. Some of the most frequently mutated genes are quite well studied, and the high rate of DNA repair gene aberrations is of particular concern because their loss leads to unstable DNA sequences.
| Drug Names | Mechanism of Action | Targets | Research Phase |
| Trastuzumab deruxtecan | Releases its cytotoxic components following the binding to and entry into the HER2-positive cells. | HER2 | Approved |
| Pembrolizumab | Blocking the programmed death receptor-1 receptor. | PD-1 | Phase III |
| Bemarituzumab | Selectively inhibits FGFR2b signaling. | FGFR | Phase III |
| Laminaran | Mitigated the gastric dysplasia’s development. | / | Preclinical |
| siCOX-2 | Inhibited the proliferation, migration, and invasion of gastric adenocarcinoma cells. | COX-2 | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Adhering to stringent quality standards, we apply innovative gastric adenocarcinoma drug research and development approaches and use new techniques that aid the advancement of high-quality reliable services and facilitate project progress. Additionally, we provide services for the development of diagnostics, therapeutics, and disease models to cater to the unique needs of researchers and organizations focusing on the research of gastric adenocarcinoma.
Animal models are crucial in understanding the pathology of gastric cancer and developing prevention and therapeutic strategies. We specialize in providing animal model development services that closely mimic the characteristics of gastric adenocarcinoma for preclinical studies and drug development purposes.
Transplant model
Additionally carrying out pharmacokinetic research and providing drug safety evaluations, Protheragen provides our customers with carefully tailored services to what they need. Offering our expertise, quality, and commitment to the advancement of science in the gastric adenocarcinoma research field in support of your research efforts. If you are interested in our services, please feel free to contact us for more details.
Reference
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.